Shares of Evolent Health (EVH) took a sharp dive in Tuesday's trading session, plummeting 5.15% following a significant downgrade from UBS. The healthcare company's stock faced heavy selling pressure as investors reacted to the revised outlook from the Swiss investment bank.

UBS analysts cut their target price for Evolent Health by a substantial 33%, lowering it from $15 to $10. This dramatic reduction in price target suggests that UBS has become considerably more pessimistic about Evolent Health's near-term prospects. The downgrade, announced before the market opened on Tuesday, likely contributed to the negative sentiment surrounding the stock throughout the trading day.

The sharp decline in Evolent Health's stock price reflects investors' immediate response to the UBS downgrade. As the market digests this new information, it remains to be seen how this will impact the company's longer-term valuation and investor confidence. Shareholders and potential investors will likely be closely monitoring any further analyst revisions or company updates in the coming days.